The purpose of this clinical trial is to demonstrate the benefit of the immunotherapeutic product GSK1572932A when given to patients with non-small cell lung cancer, after removal of their tumor.

This is a double-blind, randomized, placebo-controlled Phase III study.

Study Requirements

A course of 13 injections will be administered over 27 months.

For more information, contact Stacy Drew at 919-684-1988.